Every year more than $250 billion was spent on cancer in the United States. In general, more than 90% of cancer-related deaths are related to metastasis. Metastatic precursors in the bloodstream can potentially be pivotal in early cancer detection, personalized medicine and minimal residual disease monitoring. Compared to fresh tissue biopsy, “liquid biopsy” of bio-markers in blood samples is much more accessible and affordable, and is much less invasive.
Our highly sensitive and cost-effective biosensor platform targets at liquid biopsy in clinical applications.